About Twist Bioscience Corporation
https://www.twistbioscience.comTwist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip.
CEO
Emily Marine Leproust
Compensation Summary
(Year 2025)
ETFs Holding This Stock
Summary
Showing Top 3 of 163
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Guggenheim
Buy
Goldman Sachs
Buy
Evercore ISI Group
Outperform
Baird
Outperform
Scotiabank
Sector Outperform
Barclays
Overweight
Grade Summary
Showing Top 6 of 7
Price Target
Institutional Ownership
ARK INVESTMENT MANAGEMENT LLC
Shares:6.73M
Value:$269.27M
ARTISAN PARTNERS LIMITED PARTNERSHIP
Shares:6.41M
Value:$256.63M
BLACKROCK, INC.
Shares:6.18M
Value:$247.32M
Summary
Showing Top 3 of 283
About Twist Bioscience Corporation
https://www.twistbioscience.comTwist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q4-2025 | $99.01M ▲ | $80.77M ▼ | $-27.14M ▼ | -27.41% ▼ | $-0.45 ▼ | $-20.88M ▼ |
| Q3-2025 | $96.06M ▲ | $81.42M ▼ | $20.39M ▲ | 21.23% ▲ | $0.34 ▲ | $26.38M ▲ |
| Q2-2025 | $92.79M ▲ | $87.59M ▲ | $-39.33M ▼ | -42.38% ▼ | $-0.66 ▼ | $-32.61M ▼ |
| Q1-2025 | $88.71M ▲ | $77.48M ▲ | $-31.59M ▲ | -35.61% ▲ | $-0.53 ▲ | $-25.09M ▲ |
| Q4-2024 | $84.71M | $74.28M | $-34.66M | -40.91% | $-0.6 | $-28.07M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q4-2025 | $232.43M ▼ | $641.86M ▼ | $168.9M ▲ | $472.96M ▼ |
| Q3-2025 | $250.8M ▼ | $643.61M ▲ | $165.41M ▲ | $478.2M ▲ |
| Q2-2025 | $257.15M ▼ | $595.62M ▼ | $155.51M ▲ | $440.11M ▼ |
| Q1-2025 | $270.83M ▼ | $608.58M ▼ | $152.64M ▲ | $455.94M ▼ |
| Q4-2024 | $276.4M | $614.32M | $141.63M | $472.69M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q4-2025 | $-27.14M ▼ | $-11.81M ▼ | $-12.4M ▼ | $5.57M ▲ | $-18.48M ▼ | $-24.24M ▼ |
| Q3-2025 | $20.39M ▲ | $-1.4M ▲ | $-9.4M ▼ | $1.83M ▼ | $-9.04M ▲ | $-10.56M ▲ |
| Q2-2025 | $-39.33M ▼ | $-12.99M ▲ | $-1.43M ▲ | $3.2M ▼ | $-11.11M ▼ | $-17.13M ▲ |
| Q1-2025 | $-31.59M ▲ | $-21.43M ▼ | $-1.54M ▼ | $17.94M ▲ | $-5.07M ▲ | $-23.7M ▼ |
| Q4-2024 | $-34.66M | $-15.32M | $-1.28M | $3.63M | $-12.9M | $-17.32M |
Revenue by Products
| Product | Q1-2025 | Q2-2025 | Q3-2025 | Q4-2025 |
|---|---|---|---|---|
 Antibody Discovery | $10.00M ▲ | $10.00M ▲ | $10.00M ▲ | $10.00M ▲ |
 Dna And Biopharma Libraries | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
 Ngs Tools | $50.00M ▲ | $50.00M ▲ | $60.00M ▲ | $50.00M ▼ |
 Oligo Pools | $10.00M ▲ | $0 ▼ | $10.00M ▲ | $10.00M ▲ |
 Synthetic Genes | $30.00M ▲ | $30.00M ▲ | $30.00M ▲ | $30.00M ▲ |
Revenue by Geography
| Region | Q1-2025 | Q2-2025 | Q3-2025 | Q4-2025 |
|---|---|---|---|---|
 Americas | $50.00M ▲ | $60.00M ▲ | $60.00M ▲ | $60.00M ▲ |
 Asia Pacific | $10.00M ▲ | $10.00M ▲ | $10.00M ▲ | $10.00M ▲ |
 EMEA | $30.00M ▲ | $30.00M ▲ | $30.00M ▲ | $30.00M ▲ |
CEO
Emily Marine Leproust
Compensation Summary
(Year 2025)
ETFs Holding This Stock
Summary
Showing Top 3 of 163
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Guggenheim
Buy
Goldman Sachs
Buy
Evercore ISI Group
Outperform
Baird
Outperform
Scotiabank
Sector Outperform
Barclays
Overweight
Grade Summary
Showing Top 6 of 7
Price Target
Institutional Ownership
ARK INVESTMENT MANAGEMENT LLC
Shares:6.73M
Value:$269.27M
ARTISAN PARTNERS LIMITED PARTNERSHIP
Shares:6.41M
Value:$256.63M
BLACKROCK, INC.
Shares:6.18M
Value:$247.32M
Summary
Showing Top 3 of 283